MedTrace Logo

Effective OnabotulinumtoxinA Dose Response Study for Upper Facial Wrinkles

NCT04994990 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-10-16

No results posted yet for this study

Summary

This research is being done to determine if lower doses of botox than what is currently recommended can give similar results to patients, at lower cost and lower risk to them. Subjects will receive botox in the same areas of the upper face with standard doses on one side of the face. On the other side, double the botox concentration will be administered, free of charge to the participant, in order to see if the difference in concentration creates a difference in wrinkle reduction and participant satisfaction over time.

Conditions

  • Rhytides

Interventions

DRUG

OnabotulinumtoxinA Standard Dose

Active comparator group will be treated for full upper face wrinkles with standard recommended doing of onabotulinumtoxinA

DRUG

OnabotulinumtoxinA Half Standard Dose

Experimental group will be treated for full upper face wrinkles with half of the standard recommended doing of onabotulinumtoxinA

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Principal Investigators

  • Nicholas Bastidas, MD · Northwell Health

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-25
Primary Completion
2024-11-30
Completion
2025-05-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04994990 on ClinicalTrials.gov